• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Pediatrics  • Neonatology and Infant Care  • Women's Health  • Pregnancy and Breast Feeding  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Pediatr Adolesc Med. 2006;160:855-856.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Levinson-Castiel et al¹ reported neonatal abstinence syndrome (NAS) in 30% of selective serotonin reuptake inhibitor (SSRI)–exposed neonates in late pregnancy using the Finnegan NAS score. Although other reports exist of antidepressant-exposed neonates having a positive Finnegan score,² the score was designed to assess opiates and not SSRI withdrawal. Moreover, the fact that newborns exposed to SSRIs in late pregnancy share some clinical features compatible with NAS does not indicate that the Finnegan score is representative of the same prevalence of symptoms or that all important symptoms are taken into account. We are currently analyzing data from a retrospective cohort of 66 SSRI- or serotonin-norepinephrine reuptake inhibitor–exposed newborns in late pregnancy; more than 20% showed decreased reactivity and/or decreased tonus during the first 72 hours of life, symptoms that are not assessed by the Finnegan score. Newborns also showed symptoms compatible with NAS in that time frame. Decreased reactivity or tonus . . . [Full Text of this Article]

AUTHOR INFORMATION

Louise Beaulac-Baillargeon, BPharm, PhD; Nina Boucher, BPharm, MSc

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Neonatal Adverse Reactions After In Utero Exposure to Selective Serotonin Reuptake Inhibitors: Still Controversial—Reply
Gil Klinger, Rachel Levinson-Castiel, and Paul Merlob
Arch Pediatr Adolesc Med. 2006;160(8):856.
EXTRACT | FULL TEXT  

Neonatal Abstinence Syndrome After In Utero Exposure to Selective Serotonin Reuptake Inhibitors in Term Infants
Rachel Levinson-Castiel, Paul Merlob, Nehama Linder, Lea Sirota, and Gil Klinger
Arch Pediatr Adolesc Med. 2006;160(2):173-176.
ABSTRACT | FULL TEXT